bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:BLUE
- CUSIP: N/A
- Web: www.bluebirdbio.com
Capitalization:- Market Cap: $5.86963 billion
- Outstanding Shares: 45,589,000
Average Prices:- 50 Day Moving Avg: $108.37
- 200 Day Moving Avg: $97.10
- 52 Week Range: $37.05 - $136.85
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -18.03
- P/E Growth: 0.29
Sales & Book Value:- Annual Revenue: $26.65 million
- Price / Sales: 220.25
- Book Value: $26.35 per share
- Price / Book: 4.89
Profitability:- EBIDTA: ($259,890,000.00)
- Net Margins: -1,080.59%
- Return on Equity: -32.19%
- Return on Assets: -25.23%
Debt:- Current Ratio: 14.37%
- Quick Ratio: 14.37%
Misc:- Average Volume: 947,998 shs.
- Beta: 2.04
- Short Ratio: 8.97
Frequently Asked Questions for bluebird bio (NASDAQ:BLUE)
What is bluebird bio's stock symbol?
bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."
How were bluebird bio's earnings last quarter?
bluebird bio, Inc. (NASDAQ:BLUE) issued its earnings results on Wednesday, August, 2nd. The company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.66) by $0.07. The firm earned $16.70 million during the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The firm's revenue was up 977.4% compared to the same quarter last year. During the same period last year, the business earned ($1.59) EPS. View bluebird bio's Earnings History.
When will bluebird bio make its next earnings announcement?
Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?
21 equities research analysts have issued 12-month price targets for bluebird bio's shares. Their predictions range from $39.00 to $158.00. On average, they anticipate bluebird bio's stock price to reach $107.33 in the next year. View Analyst Ratings for bluebird bio.
What are analysts saying about bluebird bio stock?
Here are some recent quotes from research analysts about bluebird bio stock:
- 1. Cantor Fitzgerald analysts commented, "LentiGlobin R&D, A Costly Endeavor. From 2014 to 2016, LentiGlobin has accounted for approximately $127 million in direct R&D expenditures. While these expenditures for LentiGlobin have been substantial, they remain only a portion of total direct R&D ($240 million) and reported accounting R&D ($401 million). Given the 23 patients dosed with the gene therapy by ASH 2016, LentiGlobin amounted to an expense of $5.5 million per patient dosed. We estimate approximately 127 patients could be required to complete development for these programs, amounting to a cost of ~$700 million. We believe R&D estimates could accelerate and model for a slightly increased burn over future years." (7/24/2017)
- 2. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (7/18/2017)
- 3. BTIG Research analysts commented, "generally captured" data updates from ASCO and EHA. Positive On Outlook But Not Enough To Remain BullishMeanwhile, Bluebird has a "good lead" over the competition in drugs targeting anti-BCMA and a Phase 1 study of bb21217 will commence in the bottom half of 2017. But at the same time competitive efforts from rivals will also ramp up, including Kite Pharma Inc (NASDAQ: KITE), which will begin a study of a fully-human anti-BCMA CAR T therapy in the third quarter.The analyst remains "more optimistic than most" regarding the LentiGlobin program for Beta-thalassemia and Sickle-cell disease. Also, the company's broadening of its oncology efforts may be a source of concern among some investors but early success in bb2121 is indeed supportive of a "broader effort in larger markets with better defined patient populations." (6/30/2017)
- 4. Maxim Group analysts commented, "bluebird announced updated data at the ongoing ASCO (American Society of Clinical Oncology) meeting for bb2121 CAR-T in the CRB-401 Phase 1 study targeting relapsed/refractory multiple myeloma (r/r/ MM)." (6/2/2017)
Who are some of bluebird bio's key competitors?
Some companies that are related to bluebird bio include Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Axovant Sciences Ltd (AXON), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO), Halozyme Therapeutics (HALO) and Loxo Oncology (LOXO).
Who are bluebird bio's key executives?
bluebird bio's management team includes the folowing people:
- Daniel S. Lynch, Independent Chairman of the Board
- Nick Leschly, President, Chief Executive Officer, Director
- Jeffrey T. Walsh, Chief Financial and Strategy Officer and Principal Financial Officer, Principal Accounting Officer
- Susanna Gatti High, Chief Operating Officer
- Philip D. Gregory Ph.D., Chief Scientific Officer
- David M. Davidson M.D., Chief Medical Officer
- Jason F. Cole Esq., Chief Legal Officer, Secretary
- John O. Agwunobi M.D., Director
- Mary Lynne Hedley Ph.D., Director
- Douglas A. Melton, Director
Who owns bluebird bio stock?
bluebird bio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (14.73%), Capital Research Global Investors (12.03%), Baillie Gifford & Co. (11.86%), Vanguard Group Inc. (7.81%), BlackRock Inc. (7.29%) and State Street Corp (3.19%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly and Philip D Gregory. View Institutional Ownership Trends for bluebird bio.
Who sold bluebird bio stock? Who is selling bluebird bio stock?
bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Balyasny Asset Management LLC, State Street Corp, Columbus Circle Investors, Jennison Associates LLC, AXA, Candriam Luxembourg S.C.A. and Wells Fargo & Company MN. Company insiders that have sold bluebird bio stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly and Philip D Gregory. View Insider Buying and Selling for bluebird bio.
Who bought bluebird bio stock? Who is buying bluebird bio stock?
bluebird bio's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Capital Research Global Investors, Vanguard Group Inc., Voya Investment Management LLC, Laurion Capital Management LP, Baillie Gifford & Co., Marshall Wace North America L.P. and BlackRock Inc.. View Insider Buying and Selling for bluebird bio.
How do I buy bluebird bio stock?
Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is bluebird bio's stock price today?
One share of bluebird bio stock can currently be purchased for approximately $128.75.
MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for bluebird bio (NASDAQ:BLUE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 6 Hold Ratings, 13 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.52) |
| Consensus Price Target: | $107.33 (16.64% downside) |
Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/6/2017 | Barclays PLC | Initiated Coverage | Overweight | $151.00 | Low |  |
| 9/5/2017 | Wells Fargo & Company | Reiterated Rating | Outperform -> Outperform | $134.00 -> $158.00 | Medium | |
| 9/1/2017 | Wedbush | Reiterated Rating | Outperform | $121.00 -> $135.00 | High | |
| 8/31/2017 | Cowen and Company | Reiterated Rating | Outperform | | High | |
| 8/16/2017 | Evercore ISI | Initiated Coverage | In -> In-Line | $102.00 | High | |
| 8/11/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $88.00 | Medium | |
| 8/9/2017 | Morgan Stanley | Reiterated Rating | Hold | | High | |
| 8/4/2017 | BMO Capital Markets | Reiterated Rating | Buy | $108.00 | Medium | |
| 7/27/2017 | Sanford C. Bernstein | Initiated Coverage | Market Perform | $109.00 | High | |
| 7/24/2017 | Cantor Fitzgerald | Reiterated Rating | Sell | $39.00 | High | |
| 6/30/2017 | BTIG Research | Downgrade | Buy -> Neutral | $37.05 -> $108.25 | Medium | |
| 6/26/2017 | Janney Montgomery Scott | Set Price Target | Buy | $125.00 | N/A | |
| 6/16/2017 | Standpoint Research | Reiterated Rating | Buy -> Reduce | $110.00 | Low | |
| 6/5/2017 | Bank of America Corporation | Reiterated Rating | Hold | $95.00 | High | |
| 6/2/2017 | Maxim Group | Upgrade | Hold -> Buy | $100.00 | High | |
| 2/23/2017 | Roth Capital | Set Price Target | Hold | $71.00 | N/A | |
| 12/7/2016 | J P Morgan Chase & Co | Reiterated Rating | Buy | $120.00 | N/A | |
| 12/1/2016 | Leerink Swann | Boost Price Target | Outperform | $80.00 -> $85.00 | N/A | |
| 11/30/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $95.00 | N/A | |
| 10/15/2016 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Buy | $135.00 | N/A | |
| 10/14/2016 | SunTrust Banks, Inc. | Reiterated Rating | Buy | | N/A | |
| 11/5/2015 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $162.00 | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for bluebird bio (NASDAQ:BLUE)Earnings History by Quarter for bluebird bio (NASDAQ BLUE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($1.68) | | | | | N/A | |
| 8/2/2017 | Q2 2017 | ($1.66) | ($1.73) | $6.29 million | $16.70 million | View | N/A | |
| 5/3/2017 | Q1 2017 | ($1.76) | ($1.68) | $1.51 million | $6.83 million | View | N/A | |
| 2/22/2017 | Q4 2016 | ($1.86) | ($1.88) | $1.76 million | $1.55 million | View | N/A | |
| 11/2/2016 | Q3 2016 | ($1.59) | ($2.07) | $1.82 million | $1.55 million | View | N/A | |
| 8/3/2016 | Q2 | ($1.44) | ($1.59) | $2.01 million | $1.55 million | View | N/A | |
| 5/4/2016 | Q1 | ($1.23) | ($1.52) | $4.50 million | $1.50 million | View | N/A | |
| 2/24/2016 | Q4 | ($1.11) | ($1.29) | $3.21 million | $1.47 million | View | N/A | |
| 11/4/2015 | Q3 | ($0.96) | ($1.18) | $5.63 million | $1.30 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.78) | ($1.57) | $8.60 million | $4.94 million | View | N/A | |
| 5/6/2015 | Q115 | ($0.68) | ($0.76) | $6.20 million | $6.30 million | View | N/A | |
| 2/25/2015 | Q414 | ($0.62) | ($0.66) | $6.20 million | $6.30 million | View | N/A | |
| 11/12/2014 | Q314 | ($0.52) | ($0.61) | $6.20 million | $6.40 million | View | N/A | |
| 8/12/2014 | Q214 | ($0.45) | ($0.06) | $6.15 million | $6.30 million | View | N/A | |
| 5/13/2014 | Q114 | ($0.32) | ($0.44) | $6.23 million | $6.30 million | View | N/A | |
| 3/5/2014 | | ($0.31) | ($0.34) | | | View | N/A | |
| 11/12/2013 | Q3 | ($0.25) | ($0.26) | $5.59 million | $6.39 million | View | N/A | |
| 8/8/2013 | Q213 | ($0.35) | ($2.13) | $4.85 million | $6.30 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for bluebird bio (NASDAQ:BLUE)2017 EPS Consensus Estimate: ($7.28)
2018 EPS Consensus Estimate: ($7.30)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | ($1.88) | ($1.79) | ($1.83) |
| Q2 2017 | 5 | ($1.89) | ($1.60) | ($1.75) |
| Q3 2017 | 5 | ($1.94) | ($1.73) | ($1.82) |
| Q4 2017 | 5 | ($2.03) | ($1.78) | ($1.88) |
| Q1 2018 | 1 | ($1.78) | ($1.78) | ($1.78) |
| Q2 2018 | 1 | ($1.81) | ($1.81) | ($1.81) |
| Q3 2018 | 1 | ($1.84) | ($1.84) | ($1.84) |
| Q4 2018 | 1 | ($1.87) | ($1.87) | ($1.87) |
(Data provided by Zacks Investment Research)
Dividend History for bluebird bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for bluebird bio (NASDAQ:BLUE)Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/14/2017 | John Maraganore | Director | Sell | 18,868 | $131.21 | $2,475,670.28 | |
| 9/12/2017 | Mark Vachon | Director | Sell | 6,000 | $126.82 | $760,920.00 | |
| 9/11/2017 | Jeffrey T Walsh | Insider | Sell | 4,900 | $125.73 | $616,077.00 | |
| 9/1/2017 | Nick Leschly | Insider | Sell | 46,833 | $122.27 | $5,726,270.91 | |
| 8/31/2017 | Daniel Lynch | Director | Sell | 500 | $120.00 | $60,000.00 | |
| 8/31/2017 | Jeffrey T Walsh | Insider | Sell | 12,000 | $125.01 | $1,500,120.00 | |
| 8/30/2017 | Nick Leschly | Insider | Sell | 25,667 | $115.18 | $2,956,325.06 | |
| 8/28/2017 | Jeffrey T Walsh | Insider | Sell | 1,250 | $107.06 | $133,825.00 | |
| 8/14/2017 | James Mandell | Director | Sell | 1,000 | $95.95 | $95,950.00 | |
| 8/10/2017 | Jeffrey T Walsh | Insider | Sell | 1,250 | $95.41 | $119,262.50 | |
| 8/7/2017 | Philip D Gregory | Insider | Sell | 750 | $99.00 | $74,250.00 | |
| 8/4/2017 | Eric Sullivan | Insider | Sell | 861 | $93.83 | $80,787.63 | |
| 8/1/2017 | David Davidson | Insider | Sell | 3,000 | $92.37 | $277,110.00 | |
| 7/10/2017 | Jeffrey T Walsh | Insider | Sell | 2,500 | $99.89 | $249,725.00 | |
| 7/7/2017 | David Davidson | Insider | Sell | 1,200 | $100.49 | $120,588.00 | |
| 7/6/2017 | Philip D Gregory | Insider | Sell | 2,250 | $103.83 | $233,617.50 | |
| 7/5/2017 | David Davidson | Insider | Sell | 5,000 | $105.28 | $526,400.00 | |
| 6/29/2017 | Eric Sullivan | Insider | Sell | 6,787 | $108.96 | $739,511.52 | |
| 6/27/2017 | Nick Leschly | Insider | Sell | 25,000 | $108.05 | $2,701,250.00 | |
| 6/23/2017 | Daniel Lynch | Director | Sell | 4,000 | $109.09 | $436,360.00 | |
| 6/20/2017 | Daniel Lynch | Director | Sell | 2,500 | $120.03 | $300,075.00 | |
| 6/7/2017 | Jason Cole | Insider | Sell | 17,245 | $100.22 | $1,728,293.90 | |
| 6/6/2017 | Daniel Lynch | Director | Sell | 2,263 | $100.14 | $226,616.82 | |
| 6/6/2017 | Philip D Gregory | Insider | Sell | 1,500 | $99.04 | $148,560.00 | |
| 6/5/2017 | David Davidson | Insider | Sell | 1,000 | $90.00 | $90,000.00 | |
| 5/25/2017 | Daniel Lynch | Director | Sell | 2,000 | $80.00 | $160,000.00 | |
| 4/27/2017 | Daniel Lynch | Director | Sell | 1,000 | $90.01 | $90,010.00 | |
| 4/25/2017 | Daniel Lynch | Director | Sell | 2,000 | $86.75 | $173,500.00 | |
| 4/10/2017 | Jeffrey T Walsh | Insider | Sell | 1,250 | $87.38 | $109,225.00 | |
| 4/3/2017 | David Davidson | Insider | Sell | 3,000 | $90.89 | $272,670.00 | |
| 3/27/2017 | Daniel Lynch | Director | Sell | 3,000 | $88.12 | $264,360.00 | |
| 3/16/2017 | Daniel Lynch | Director | Sell | 237 | $100.07 | $23,716.59 | |
| 3/16/2017 | Jason Cole | Insider | Sell | 4,930 | $100.07 | $493,345.10 | |
| 3/3/2017 | John Maraganore | Director | Sell | 13,839 | $85.02 | $1,176,591.78 | |
| 2/15/2017 | Daniel Lynch | Director | Sell | 150 | $80.22 | $12,033.00 | |
| 2/15/2017 | Jason Cole | Insider | Sell | 666 | $80.22 | $53,426.52 | |
| 2/14/2017 | Daniel Lynch | Director | Sell | 850 | $80.01 | $68,008.50 | |
| 2/14/2017 | Jason Cole | Insider | Sell | 3,772 | $80.01 | $301,797.72 | |
| 1/31/2017 | James Mandell | Director | Sell | 8,000 | $75.04 | $600,320.00 | |
| 1/27/2017 | Daniel Lynch | Director | Sell | 1,000 | $70.09 | $70,090.00 | |
| 1/27/2017 | David Davidson | Insider | Sell | 6,000 | $69.02 | $414,120.00 | |
| 1/5/2017 | Jason Cole | Insider | Sell | 549 | $67.10 | $36,837.90 | |
| 10/3/2016 | Eric Sullivan | Insider | Sell | 416 | $67.00 | $27,872.00 | |
| 9/13/2016 | Eric Sullivan | Insider | Sell | 416 | $59.00 | $24,544.00 | |
| 8/3/2016 | Eric Sullivan | Insider | Sell | 416 | $59.00 | $24,544.00 | |
| 7/27/2016 | Eric Sullivan | Insider | Sell | 2,912 | $55.01 | $160,189.12 | |
| 7/20/2016 | Eric Sullivan | Insider | Sell | 2,807 | $45.04 | $126,427.28 | |
| 7/15/2016 | David Davidson | Insider | Sell | 1,000 | $45.08 | $45,080.00 | |
| 6/16/2016 | Philip D Gregory | Insider | Sell | 2,931 | $39.52 | $115,833.12 | |
| 6/15/2016 | David Davidson | Insider | Sell | 1,000 | $40.11 | $40,110.00 | |
| 5/16/2016 | David Davidson | Insider | Sell | 1,000 | $38.73 | $38,730.00 | |
| 4/15/2016 | David Davidson | Insider | Sell | 1,000 | $49.63 | $49,630.00 | |
| 3/15/2016 | David Davidson | Insider | Sell | 1,000 | $46.13 | $46,130.00 | |
| 2/16/2016 | David Davidson | insider | Sell | 1,000 | $45.18 | $45,180.00 | |
| 1/15/2016 | David Davidson | insider | Sell | 1,000 | $44.39 | $44,390.00 | |
| 12/15/2015 | David Davidson | insider | Sell | 1,000 | $58.55 | $58,550.00 | |
| 12/8/2015 | Nick Leschly | CEO | Buy | 9,682 | $51.75 | $501,043.50 | |
| 11/16/2015 | David Davidson | insider | Sell | 2,000 | $70.99 | $141,980.00 | |
| 11/10/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $74.60 | $820,600.00 | |
| 10/15/2015 | David Davidson | insider | Sell | 2,000 | $79.70 | $159,400.00 | |
| 10/12/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $88.06 | $968,660.00 | |
| 10/9/2015 | Jason Cole | SVP | Sell | 5,000 | $86.91 | $434,550.00 | |
| 10/5/2015 | Daniel Lynch | Director | Sell | 3,000 | $100.41 | $301,230.00 | |
| 9/17/2015 | Daniel Lynch | Director | Sell | 1,500 | $140.06 | $210,090.00 | |
| 9/15/2015 | David Davidson | insider | Sell | 2,000 | $129.98 | $259,960.00 | |
| 9/10/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $130.02 | $1,430,220.00 | |
| 9/9/2015 | Jason Cole | SVP | Sell | 2,000 | $136.56 | $273,120.00 | |
| 9/8/2015 | Daniel Lynch | Director | Sell | 7,000 | $132.75 | $929,250.00 | |
| 9/8/2015 | Nick Leschly | CEO | Sell | 125,000 | $135.24 | $16,905,000.00 | |
| 9/1/2015 | James Mandell | Director | Sell | 1,500 | $125.96 | $188,940.00 | |
| 7/20/2015 | Eric Sullivan | Insider | Sell | 1,126 | $163.36 | $183,943.36 | |
| 7/15/2015 | David Davidson | Insider | Sell | 2,000 | $165.96 | $331,920.00 | |
| 7/10/2015 | Jeffrey T Walsh | COO | Sell | 11,000 | $158.63 | $1,744,930.00 | |
| 7/9/2015 | Jason Cole | SVP | Sell | 5,000 | $158.19 | $790,950.00 | |
| 6/15/2015 | David Davidson | Insider | Sell | 2,000 | $183.34 | $366,680.00 | |
| 6/10/2015 | Jeffrey T Walsh | COO | Sell | 11,000 | $179.70 | $1,976,700.00 | |
| 6/1/2015 | Mitchell H Finer | Insider | Sell | 15,000 | $190.25 | $2,853,750.00 | |
| 4/20/2015 | Mitchell H Finer | Insider | Sell | 15,000 | $126.03 | $1,890,450.00 | |
| 4/15/2015 | David Davidson | Insider | Sell | 2,000 | $130.18 | $260,360.00 | |
| 4/10/2015 | Jeffrey T Walsh | COO | Sell | 21,000 | $126.21 | $2,650,410.00 | |
| 4/2/2015 | Eric Sullivan | Insider | Sell | 2,998 | $117.81 | $353,194.38 | |
| 3/10/2015 | Jeffrey T Walsh | COO | Sell | 10,500 | $110.06 | $1,155,630.00 | |
| 3/2/2015 | David Davidson | Insider | Sell | 4,000 | $94.84 | $379,360.00 | |
| 1/12/2015 | Jeffrey T Walsh | COO | Sell | 10,500 | $103.57 | $1,087,485.00 | |
| 1/2/2015 | David Davidson | Insider | Sell | 4,000 | $90.01 | $360,040.00 | |
| 12/19/2014 | John Maraganore | Director | Buy | 2,352 | $85.00 | $199,920.00 | |
| 12/10/2014 | Jeffrey T Walsh | COO | Sell | 43,500 | $78.06 | $3,395,610.00 | |
| 12/8/2014 | David Davidson | Insider | Sell | 15,000 | $46.10 | $691,500.00 | |
| 12/3/2014 | David Davidson | Insider | Sell | 3,000 | $41.65 | $124,950.00 | |
| 12/1/2014 | Mitchell H Finer | Insider | Sell | 18,000 | $39.70 | $714,600.00 | |
| 12/1/2014 | Nick Leschly | CEO | Sell | 2,417 | $39.70 | $95,954.90 | |
| 11/3/2014 | David Davidson | Insider | Sell | 3,000 | $41.68 | $125,040.00 | |
| 11/3/2014 | Nick Leschly | CEO | Sell | 25,000 | $41.68 | $1,042,000.00 | |
| 10/24/2014 | Nick Leschly | CEO | Sell | 33,900 | $40.22 | $1,363,458.00 | |
| 10/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $33.16 | $248,700.00 | |
| 10/9/2014 | Steven Gillis | Director | Sell | 115,000 | $35.25 | $4,053,750.00 | |
| 10/8/2014 | Mitchell H Finer | Insider | Sell | 34,518 | $33.52 | $1,157,043.36 | |
| 10/7/2014 | Steven Gillis | Director | Sell | 57,435 | $35.43 | $2,034,922.05 | |
| 10/2/2014 | Steven Gillis | Director | Sell | 91,165 | $35.28 | $3,216,301.20 | |
| 10/1/2014 | David Davidson | Insider | Sell | 3,000 | $34.55 | $103,650.00 | |
| 10/1/2014 | Nick Leschly | CEO | Sell | 8,000 | $34.55 | $276,400.00 | |
| 9/12/2014 | Robert I Tepper | Director | Sell | 125,000 | $36.54 | $4,567,500.00 | |
| 9/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $37.02 | $277,650.00 | |
| 9/2/2014 | David Davidson | Insider | Sell | 3,000 | $38.00 | $114,000.00 | |
| 9/2/2014 | Nick Leschly | CEO | Sell | 10,300 | $38.45 | $396,035.00 | |
| 8/11/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $34.26 | $256,950.00 | |
| 8/1/2014 | David Davidson | Insider | Sell | 3,000 | $33.62 | $100,860.00 | |
| 8/1/2014 | Nick Leschly | CEO | Sell | 8,000 | $33.62 | $268,960.00 | |
| 7/14/2014 | John Maraganore | Director | Buy | 2,941 | $34.00 | $99,994.00 | |
| 7/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $33.20 | $249,000.00 | |
| 7/3/2014 | Nick Leschly | CEO | Sell | 22,283 | $39.86 | $888,200.38 | |
| 7/1/2014 | David Davidson | Insider | Sell | 3,000 | $39.55 | $118,650.00 | |
| 6/20/2014 | Nick Leschly | CEO | Sell | 17,075 | $40.06 | $684,024.50 | |
| 6/16/2014 | Jeffrey T Walsh | COO | Sell | 1,500 | $39.86 | $59,790.00 | |
| 6/16/2014 | Mitchell H Finer | Insider | Sell | 10,000 | $39.84 | $398,400.00 | |
| 6/16/2014 | Nick Leschly | CEO | Sell | 42,925 | $40.02 | $1,717,858.50 | |
| 6/10/2014 | Jeffrey T Walsh | COO | Sell | 6,000 | $24.23 | $145,380.00 | |
| 6/2/2014 | Mitchell H Finer | Insider | Sell | 8,000 | $22.21 | $177,680.00 | |
| 6/2/2014 | Nick Leschly | CEO | Sell | 5,000 | $22.21 | $111,050.00 | |
| 5/14/2014 | Jeffrey Walsh | COO | Sell | 1,500 | $20.03 | $30,045.00 | |
| 5/12/2014 | Jeffrey Walsh | COO | Sell | 4,500 | $18.93 | $85,185.00 | |
| 5/1/2014 | David Davidson | Insider | Sell | 4,000 | $19.85 | $79,400.00 | |
| 5/1/2014 | Nick Leschly | CEO | Sell | 5,000 | $20.07 | $100,350.00 | |
| 4/10/2014 | Jeffrey Walsh | COO | Sell | 6,000 | $21.29 | $127,740.00 | |
| 1/22/2014 | Linda Bain | VP | Sell | 2,500 | $25.11 | $62,775.00 | |
| 1/17/2014 | Robert Tepper | Director | Sell | 307,000 | $22.43 | $6,886,010.00 | |
| 1/16/2014 | Mitchell Finer | Insider | Sell | 10,000 | $23.52 | $235,200.00 | |
| 1/14/2014 | Robert Tepper | Director | Sell | 340,000 | $21.90 | $7,446,000.00 | |
| 1/10/2014 | Jeffrey Walsh | COO | Sell | 6,000 | $21.98 | $131,880.00 | |
| 1/3/2014 | David Davidson | Insider | Sell | 15,000 | $20.88 | $313,200.00 | |
| 1/3/2014 | Linda Bain | VP | Sell | 5,000 | $20.89 | $104,450.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for bluebird bio (NASDAQ:BLUE)
Latest Headlines for bluebird bio (NASDAQ:BLUE)
| Source: |
|
| Date | Headline |
|---|
 | Reviewing bluebird bio (BLUE) & Aldeyra Therapeutics (ALDX)
www.americanbankingnews.com - September 23 at 8:32 PM |
 | bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors
finance.yahoo.com - September 20 at 5:27 PM |
| bluebird bio, Inc. (BLUE) Director Sells $2,475,670.28 in Stock
www.americanbankingnews.com - September 18 at 7:22 PM |
| bluebird bio, Inc. (BLUE) Director Mark Vachon Sells 6,000 Shares
www.americanbankingnews.com - September 14 at 10:52 PM |
 | bluebird bio (BLUE) Reports First Patient Treated in Expansion ... - StreetInsider.com
www.streetinsider.com - September 14 at 5:15 PM |
| Insider Selling: bluebird bio, Inc. (BLUE) Insider Sells 4,900 Shares of Stock
www.americanbankingnews.com - September 13 at 7:38 PM |
| bluebird bio (BLUE) Reports First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121
www.streetinsider.com - September 13 at 5:49 PM |
| bluebird bio Announces First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121
finance.yahoo.com - September 13 at 5:49 PM |
| bluebird bio, Inc. (BLUE) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 13 at 3:16 PM |
 | Is bluebird bio Overvalued? - Seeking Alpha
seekingalpha.com - September 11 at 5:18 PM |
| Zacks: Analysts Anticipate bluebird bio, Inc. (BLUE) Will Announce Quarterly Sales of $9.71 Million
www.americanbankingnews.com - September 9 at 1:04 AM |
| Brokerages Expect bluebird bio, Inc. (BLUE) to Announce -$1.59 Earnings Per Share
www.americanbankingnews.com - September 7 at 10:24 PM |
 | bluebird bio to Present Interim Clinical Data from Starbeam Study of ... - Business Wire (press release)
www.businesswire.com - September 7 at 2:43 AM |
 | Here's What Lifted bluebird bio Inc. Stock 40% Higher in August - Motley Fool
www.fool.com - September 7 at 2:43 AM |
| bluebird bio, Inc. (BLUE) Now Covered by Analysts at Barclays PLC
www.americanbankingnews.com - September 6 at 5:16 PM |
| bluebird bio (BLUE) to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in CALD at CNS Meeting
www.streetinsider.com - September 6 at 4:38 PM |
| bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy (CALD) at Child Neurology Society (CNS) 2017 Annual Meeting
finance.yahoo.com - September 6 at 4:38 PM |
| Here's What Lifted bluebird bio Inc. Stock 40% Higher in August
finance.yahoo.com - September 6 at 4:38 PM |
| bluebird bio, Inc. (BLUE) Insider Jeffrey T. Walsh Sells 12,000 Shares
www.americanbankingnews.com - September 5 at 7:22 PM |
| Insider Selling: bluebird bio, Inc. (BLUE) Director Sells 500 Shares of Stock
www.americanbankingnews.com - September 5 at 4:46 PM |
| bluebird bio, Inc. (BLUE) Insider Nick Leschly Sells 46,833 Shares
www.americanbankingnews.com - September 5 at 4:26 PM |
| bluebird bio, Inc. (BLUE) Earns "Outperform" Rating from Wells Fargo & Company
www.americanbankingnews.com - September 5 at 12:20 PM |
 | bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session
www.nasdaq.com - September 1 at 4:53 PM |
| bluebird bio to Present at Investor Conferences in September
finance.yahoo.com - September 1 at 4:53 PM |
| Wedbush Reaffirms "Outperform" Rating for bluebird bio, Inc. (BLUE)
www.americanbankingnews.com - September 1 at 10:36 AM |
| Why bluebird bio Inc Continued Its March Higher Again Today - Motley Fool
www.fool.com - August 31 at 9:36 PM |
| ETFs with exposure to bluebird bio, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 9:36 PM |
| Cowen and Company Reaffirms Outperform Rating for bluebird bio, Inc. (BLUE)
www.americanbankingnews.com - August 31 at 9:28 PM |
| bluebird bio, Inc. (BLUE) Insider Sells $2,956,325.06 in Stock
www.americanbankingnews.com - August 31 at 7:20 PM |
| Why bluebird bio Inc Continued Its March Higher Again Today
finance.yahoo.com - August 31 at 4:32 PM |
| bluebird bio, Inc. (BLUE) PT Raised to $300,000.00
www.americanbankingnews.com - August 31 at 11:22 AM |
 | FDA Approves Treatment That Modifies Patient's Own Genes To Fight Cancer
www.huffingtonpost.com - August 31 at 4:04 AM |
| Kite Pharma Acquired - bluebird bio Remains Undervalued - Seeking Alpha
seekingalpha.com - August 30 at 11:00 PM |
| Why bluebird bio Inc Jumped Higher Today - Motley Fool
www.fool.com - August 30 at 11:00 PM |
| Insider Selling: bluebird bio, Inc. (BLUE) Insider Sells 1,250 Shares of Stock
www.americanbankingnews.com - August 30 at 8:26 PM |
 | Novartis gene therapy approval signals new cancer treatment era
www.reuters.com - August 30 at 5:57 PM |
| Novartis gene therapy approval signals new cancer treatment era
www.reuters.com - August 30 at 5:57 PM |
| Novartis Wins FDA Approval for CAR-T; So Why Is Gilead Getting a Boost?
finance.yahoo.com - August 30 at 5:57 PM |
| Novartis Wins FDA Approval for CAR-T; So Why Is Gilead Getting a Boost?
finance.yahoo.com - August 30 at 5:57 PM |
| Novartis: A New $475,000 Drug
finance.yahoo.com - August 30 at 5:57 PM |
| Gilead Finally Pulls The Trigger With $12-Billion Kite Deal
seekingalpha.com - August 29 at 4:57 PM |
| Today's Research Reports on Trending Tickers: bluebird bio Inc. and Juno Therapeutics Inc.
finance.yahoo.com - August 29 at 4:56 PM |
| bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : August 29, 2017
finance.yahoo.com - August 29 at 4:56 PM |
| Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition
finance.yahoo.com - August 29 at 4:56 PM |
| Gilead to buy Kite for promising cancer therapies in $12 billion deal
www.reuters.com - August 28 at 4:34 PM |
 | Recent GILD News
www.bloomberg.com - August 28 at 4:34 PM |
| Biotech stocks surge on Gilead's Kite Pharma acquisition
finance.yahoo.com - August 28 at 4:34 PM |
| Gilead: What the Heck is CAR-T, How Much is Too Much, and Other Kite Acquisition Questions
finance.yahoo.com - August 28 at 4:34 PM |
| bluebird bio, Inc. to Post FY2017 Earnings of ($7.15) Per Share, Cantor Fitzgerald Forecasts (BLUE)
www.americanbankingnews.com - August 28 at 3:18 AM |
| bluebird bio, Inc. :BLUE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 4:41 PM |
bluebird bio (BLUE) Chart for Tuesday, September, 26, 2017
